News Grower

Independent coverage of AI, startups, and technology.

Ars Technica Jun 17, 2026 at 15:12 Big Tech Rising Hot

"Truly evil" FDA rejection of gene therapy overturned after Trump official ousted

Gene therapy company UniQure had another FDA meeting after Vinay Prasad's exit.

Signal weather

Rising

Momentum is building quickly, so this card is a good early entry point into the topic.

By Beth Mole Original source
"Truly evil" FDA rejection of gene therapy overturned after Trump official ousted

A gene therapy for Huntington's disease has a new path toward approval from the Food and Drug Administration after the ouster of several Trump officials, particularly Vinay Prasad, who rejected the therapy in a shocking move one former FDA official called "truly evil." Huntington's disease is an inherited condition that typically strikes in middle age and causes nerve cells in the brain to gradually break down. There are currently no treatments for the disease, and many afflicted die in their 50s and 60s. Gene therapy company UniQure developed a one-time treatment, AMT-130, that aims to lower brain levels of the mutant protein behind the disease, called huntingtin. Data from a small, early trial suggested the drug could slow the progression of the disease up to 75 percent, and patients and advocates have closely watched the drug's development in hopeful anticipation. Read full article Comments

Stay on the signal

Follow "Truly evil" FDA rejection of gene therapy overturned after Trump official ousted

Follow this story beyond a single article: new follow-ups, adjacent sources, and the evolving storyline.

We send a confirmation link first, then only meaningful digests.

Story map

Understand this topic fast

A quick entry into the story: why it matters now, who is involved, and where to go next for context.

Why it matters now

Fresh coverage with immediate momentum.
There are already 6 connected articles in the same storyline to continue from here.
The story keeps orbiting around Ars Technica, FDA, and Fda Rejection, so the entity pages are the fastest way to build context.
Ars Technica already has 4 follow-up stories on the same theme.

Topic constellation

Open the live map for this story

See which entities, story threads, sources, and follow-up articles shape this story right now.

Click nodes to continue

Entity Cluster Article Hub Source

Story timeline

Continue with this story

A short sequence of events and follow-up stories to understand the arc quickly.

Jun 17, 2026 at 15:57 Ars Technica

Ten months later, the $100 Google Home Speaker is finally available for preorder

Google's new smart speaker is more about Gemini than audio quality.

Jun 17, 2026 at 15:47 Ars Technica

Towers once planned for California shuttle launches leveled for SpaceX rockets

"Space Launch Complex-6 represents six decades of American innovation."

Jun 17, 2026 at 15:12 Ars Technica

"Truly evil" FDA rejection of gene therapy overturned after Trump official ousted

Gene therapy company UniQure had another FDA meeting after Vinay Prasad's exit.

Jun 17, 2026 at 12:00 Ars Technica

Native NACS ports, infotainment upgrade for MY27 Porsche Taycan

The bigger battery is standard and there are now simulated "E-Shifts."

Jun 17, 2026 at 11:15 Ars Technica

Windows and Linux users: The deadline to update Secure Boot keys is near

What you need to know about the expiration of keys securing your machine's boot sequence.

Jun 16, 2026 at 22:22 Ars Technica

Trump admin tries to block Clean Air Act lawsuit over xAI's gas turbines

NAACP lawsuit says xAI uses gas turbines without permits for Grok data center.

How reliable this looks

Signal and trust for Ars Technica

This source works at a rapid pace: 100% of recent stories land in the hot window, and 0% carry visible search signal.

Trusted

Reliability

92

Freshness

100

Sources in storyline

1

Related articles

More stories that share tags, source, or category context.

More from Ars Technica

Fresh reporting and follow-up coverage from the same newsroom.

Open source page